In this phase 3 , double-blind , randomised ALSYMPCA trial , we enrolled patients who had symptomatic castration-resistant prostate cancer with two or more bone metastases and no known visceral metastases , who were receiving best standard of care , and had previously either received or were unsuitable for docetaxel .